tiprankstipranks

Q32 Bio initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Q32 Bio with an Overweight rating and $95 price target. The firm likes the setup for the shares ahead of the “two major” Q4 Phase 2 readouts for the company’s lead program bempikibart. The Street’s odds of success are too low for these programs and the shares could more than double, the analyst tells investors in a research note. The firm says that by blocking Th1 and Th2 and affecting OX40L, bempikibart has the potential to impact acute and chronic atopic dermatitis pathogenesis while maintaining therapeutic effects and restoring immune balance.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue